These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 3663816)
41. Synergistic effect of vitamin E and selenium in the chemoprevention of mammary carcinogenesis in rats. Horvath PM; Ip C Cancer Res; 1983 Nov; 43(11):5335-41. PubMed ID: 6413056 [TBL] [Abstract][Full Text] [Related]
42. [New approaches to the drug prophylaxis of mammary tumor: evaluation of the prophylactic effect of lovastatin and captopril in rats with experimental mammary gland tumors]. Chochieva AR; Bolieva LZ; Dzhioev FK Eksp Klin Farmakol; 2008; 71(1):43-5. PubMed ID: 18365487 [TBL] [Abstract][Full Text] [Related]
43. Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. Yuri T; Tsukamoto R; Uehara N; Matsuoka Y; Tsubura A In Vivo; 2006; 20(6B):829-36. PubMed ID: 17203775 [TBL] [Abstract][Full Text] [Related]
44. Efficient inference for random-coefficient growth curve models with unbalanced data. Vonesh EF; Carter RL Biometrics; 1987 Sep; 43(3):617-28. PubMed ID: 3663819 [TBL] [Abstract][Full Text] [Related]
45. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future. Omenn GS Eur J Cancer Prev; 2007 Jun; 16(3):184-91. PubMed ID: 17415088 [TBL] [Abstract][Full Text] [Related]
46. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cohen LA; Pittman B; Wang CX; Aliaga C; Yu L; Moyer JD Cancer Res; 2001 Dec; 61(24):8683-8. PubMed ID: 11751385 [TBL] [Abstract][Full Text] [Related]
47. An application of the clumped binomial model to the analysis of clustered attribute data. Koch GG; Tolley HD; Freeman JL Biometrics; 1976 Jun; 32(2):337-54. PubMed ID: 986196 [TBL] [Abstract][Full Text] [Related]
49. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Dunnett CW; Gent M Biometrics; 1977 Dec; 33(4):593-602. PubMed ID: 588654 [TBL] [Abstract][Full Text] [Related]
50. Chemoprevention and chemotherapy of mammary tumors by monoterpenoids. Gould MN; Wacker WD; Maltzman TH Prog Clin Biol Res; 1990; 347():255-68. PubMed ID: 2217395 [No Abstract] [Full Text] [Related]
51. Mammary gland neoplasia in long-term rodent studies. Russo IH; Russo J Environ Health Perspect; 1996 Sep; 104(9):938-67. PubMed ID: 8899375 [TBL] [Abstract][Full Text] [Related]
52. Statistical analysis of animal cancer chemoprevention experiments. Freedman LS; Midthune DN; Brown CC; Steele V; Kelloff GJ Biometrics; 1993 Mar; 49(1):259-68. PubMed ID: 8513108 [TBL] [Abstract][Full Text] [Related]
53. Effect of exercise intensity and duration on the induction of mammary carcinogenesis. Thompson HJ Cancer Res; 1994 Apr; 54(7 Suppl):1960s-1963s. PubMed ID: 8137320 [TBL] [Abstract][Full Text] [Related]
54. The analysis of cancer chemoprevention experiments. Kokoska SM Biometrics; 1987 Sep; 43(3):525-34. PubMed ID: 3663816 [TBL] [Abstract][Full Text] [Related]
55. The statistical analysis of cancer inhibition/promotion experiments. Kokoska SM; Hardin JM; Grubbs CJ; Hsu C Anticancer Res; 1993; 13(5A):1357-63. PubMed ID: 8239506 [TBL] [Abstract][Full Text] [Related]
56. Retinyl ethers as cancer chemopreventive agents. Suppression of mammary cancer. Shealy YF; Frye JL; Riordan JM; Hill DL; McPhillips M; Wille JJ; Sani BP; Kalin JR; Eto I; Grubbs CJ Anticancer Drug Des; 1997 Jan; 12(1):15-33. PubMed ID: 9051111 [TBL] [Abstract][Full Text] [Related]